Landos Biopharma to Participate in the SVB Leerink 10th Annual Global Healthcare Conference

Rhea-AI Summary

Landos Biopharma (Nasdaq: LABP), a clinical-stage biopharmaceutical company, announced that Dr. Josep Bassaganya-Riera will participate in a fireside chat at the SVB Leerink 10th Annual Global Healthcare Conference on February 24, 2021, at 12:00 PM EST. A live webcast will be available on the company's website, with an archived version to follow.

Landos focuses on oral therapeutics for autoimmune diseases, with lead asset BT-11 targeting ulcerative colitis and Crohn’s disease.

BLACKSBURG, Va., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma (Nasdaq: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, today announced that Dr. Josep Bassaganya-Riera, Chairman, President and Chief Executive Officer, will participate in a fireside chat at the upcoming virtual SVB Leerink 10th Annual Global Healthcare Conference on Wednesday, February 24, 2021 at 12:00 PM EST.

A live webcast of the fireside chat will be accessible through the Investors/Media section of the Company’s website at www.landosbiopharma.com. Following the event, the webcast will be archived on the Landos website.

About Landos Biopharma

Landos Biopharma is a clinical-stage biopharmaceutical company focused on the discovery and development of oral therapeutics for patients with autoimmune diseases that are the first to target new mechanisms of action, including the LANCL2, NLRX1 and PLXDC2 immunometabolic pathways. Landos Biopharma’s core expertise is in the development of therapeutic candidates targeting novel pathways at the interface of immunity and metabolism. Lead asset BT-11 is a novel, oral, gut-restricted small molecule therapeutic candidate for the treatment of ulcerative colitis and Crohn’s disease that targets the LANCL2 pathway. NX-13 is a novel, oral, gut-restricted compound for the treatment of inflammatory bowel disease, which targets the NLRX1 pathway. Additional candidates are in development for the treatment of lupus nephritis, rheumatoid arthritis, multiple sclerosis, and diabetes.

Contacts:
Thomas Hoffmann (investors)
Solebury Trout
646-378-2931
thoffmann@troutgroup.com

Hannah Gendel (media)
Solebury Trout
646-378-2943
hgendel@troutgroup.com

FAQ

When will Landos Biopharma's fireside chat take place?

The fireside chat will occur on February 24, 2021, at 12:00 PM EST.

Where can I watch the Landos Biopharma conference webcast?

The webcast will be accessible through the Investors/Media section of the Landos Biopharma website.

What is the focus of Landos Biopharma's research?

Landos Biopharma focuses on developing oral therapeutics for autoimmune diseases.

What are Landos Biopharma's lead drug candidates?

Lead candidates include BT-11 for ulcerative colitis and NX-13 for inflammatory bowel disease.

What mechanisms do Landos Biopharma's therapeutics target?

Their therapeutics target novel immunometabolic pathways like LANCL2 and NLRX1.